Morris H, Wallach J (2014). „From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs”. Drug Testing and Analysis. 6 (7–8): 614—632. PMID24678061. doi:10.1002/dta.1620.
Davidsen AB, Mardal M, Johansen SS, Dalsgaard PW, Linnet K (јул 2020). „In vitro and in vivo metabolism and detection of 3-HO-PCP, a synthetic phencyclidine, in human samples and pooled human hepatocytes using high resolution mass spectrometry”. Drug Testing and Analysis. 12 (7): 987—993. PMID32311838. S2CID216047397. doi:10.1002/dta.2807.CS1 одржавање: Формат датума (веза)
Kamenka JM, Chiche B, Goudal R, Geneste P, Vignon J, Vincent JP, Lazdunski M (април 1982). „Chemical synthesis and molecular pharmacology of hydroxylated 1-(1-phenylcyclohexyl-piperidine derivatives”. Journal of Medicinal Chemistry. 25 (4): 431—435. PMID6279847. doi:10.1021/jm00346a019.CS1 одржавање: Формат датума (веза)
Johnson N, Itzhak Y, Pasternak GW (јун 1984). „Interaction of two phencyclidine opiate-like derivatives with 3H-opioid binding sites”. European Journal of Pharmacology. 101 (3–4): 281—284. PMID6088255. doi:10.1016/0014-2999(84)90171-7.CS1 одржавање: Формат датума (веза)
Itzhak Y, Kalir A, Sarne Y (јул 1981). „On the opioid nature of phencyclidine and its 3-hydroxy derivative”. European Journal of Pharmacology. 73 (2–3): 229—233. PMID6273187. doi:10.1016/0014-2999(81)90097-2.CS1 одржавање: Формат датума (веза)
Itzhak Y (април 1987). „[3H]PCP-3-OH and (+)[3H]SKF 10047 binding sites in rat brain membranes: evidence of multiplicity”. European Journal of Pharmacology. 136 (2): 231—234. PMID3036548. doi:10.1016/0014-2999(87)90715-1.CS1 одржавање: Формат датума (веза)
Itzhak Y (1988). „Pharmacological specificity of some psychotomimetic and antipsychotic agents for the sigma and PCP binding sites”. Life Sciences. 42 (7): 745—752. PMID2893238. doi:10.1016/0024-3205(88)90646-7.
Holsztynska EJ, Domino EF (1985). „Biotransformation of phencyclidine”. Drug Metabolism Reviews. 16 (3): 285—320. PMID3914938. doi:10.3109/03602538508991437.
Holsztynska EJ, Domino EF (1986). „Quantitation of phencyclidine, its metabolites, and derivatives by gas chromatography with nitrogen-phosphorus detection: application for in vivo and in vitro biotransformation studies”. Journal of Analytical Toxicology. 10 (3): 107—115. PMID3724069. doi:10.1093/jat/10.3.107.
nih.gov
ncbi.nlm.nih.gov
Morris H, Wallach J (2014). „From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs”. Drug Testing and Analysis. 6 (7–8): 614—632. PMID24678061. doi:10.1002/dta.1620.
Davidsen AB, Mardal M, Johansen SS, Dalsgaard PW, Linnet K (јул 2020). „In vitro and in vivo metabolism and detection of 3-HO-PCP, a synthetic phencyclidine, in human samples and pooled human hepatocytes using high resolution mass spectrometry”. Drug Testing and Analysis. 12 (7): 987—993. PMID32311838. S2CID216047397. doi:10.1002/dta.2807.CS1 одржавање: Формат датума (веза)
Kamenka JM, Chiche B, Goudal R, Geneste P, Vignon J, Vincent JP, Lazdunski M (април 1982). „Chemical synthesis and molecular pharmacology of hydroxylated 1-(1-phenylcyclohexyl-piperidine derivatives”. Journal of Medicinal Chemistry. 25 (4): 431—435. PMID6279847. doi:10.1021/jm00346a019.CS1 одржавање: Формат датума (веза)
Johnson N, Itzhak Y, Pasternak GW (јун 1984). „Interaction of two phencyclidine opiate-like derivatives with 3H-opioid binding sites”. European Journal of Pharmacology. 101 (3–4): 281—284. PMID6088255. doi:10.1016/0014-2999(84)90171-7.CS1 одржавање: Формат датума (веза)
Itzhak Y, Kalir A, Sarne Y (јул 1981). „On the opioid nature of phencyclidine and its 3-hydroxy derivative”. European Journal of Pharmacology. 73 (2–3): 229—233. PMID6273187. doi:10.1016/0014-2999(81)90097-2.CS1 одржавање: Формат датума (веза)
Itzhak Y, Hiller JM, Simon EJ (јануар 1985). „Characterization of specific binding sites for [3H](d)-N-allylnormetazocine in rat brain membranes”. Molecular Pharmacology. 27 (1): 46—52. PMID3965930.CS1 одржавање: Формат датума (веза)
Itzhak Y (април 1987). „[3H]PCP-3-OH and (+)[3H]SKF 10047 binding sites in rat brain membranes: evidence of multiplicity”. European Journal of Pharmacology. 136 (2): 231—234. PMID3036548. doi:10.1016/0014-2999(87)90715-1.CS1 одржавање: Формат датума (веза)
Itzhak Y (1988). „Pharmacological specificity of some psychotomimetic and antipsychotic agents for the sigma and PCP binding sites”. Life Sciences. 42 (7): 745—752. PMID2893238. doi:10.1016/0024-3205(88)90646-7.
Holsztynska EJ, Domino EF (1985). „Biotransformation of phencyclidine”. Drug Metabolism Reviews. 16 (3): 285—320. PMID3914938. doi:10.3109/03602538508991437.
Holsztynska EJ, Domino EF (1986). „Quantitation of phencyclidine, its metabolites, and derivatives by gas chromatography with nitrogen-phosphorus detection: application for in vivo and in vitro biotransformation studies”. Journal of Analytical Toxicology. 10 (3): 107—115. PMID3724069. doi:10.1093/jat/10.3.107.
semanticscholar.org
api.semanticscholar.org
Davidsen AB, Mardal M, Johansen SS, Dalsgaard PW, Linnet K (јул 2020). „In vitro and in vivo metabolism and detection of 3-HO-PCP, a synthetic phencyclidine, in human samples and pooled human hepatocytes using high resolution mass spectrometry”. Drug Testing and Analysis. 12 (7): 987—993. PMID32311838. S2CID216047397. doi:10.1002/dta.2807.CS1 одржавање: Формат датума (веза)